Comparing Insulet (NASDAQ:PODD) & Stagezero Life Sciences (OTCMKTS:SZLSF)

Stagezero Life Sciences (OTCMKTS:SZLSF) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Profitability

This table compares Stagezero Life Sciences and Insulet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stagezero Life Sciences	N/A	N/A	N/A
Insulet	9.76%	24.36%	10.02%

Earnings & Valuation

This table compares Stagezero Life Sciences and Insulet”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stagezero Life Sciences	N/A	N/A	N/A	($0.01)	-0.05
Insulet	$2.07 billion	10.16	$418.30 million	$3.45	86.72

Insulet has higher revenue and earnings than Stagezero Life Sciences. Stagezero Life Sciences is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Stagezero Life Sciences and Insulet, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stagezero Life Sciences	0	0	0	0	0.00
Insulet	0	3	21	0	2.88

Insulet has a consensus price target of $381.75, indicating a potential upside of 27.60%. Given Insulet’s stronger consensus rating and higher probable upside, analysts plainly believe Insulet is more favorable than Stagezero Life Sciences.

Volatility and Risk

Stagezero Life Sciences has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.

Summary

Insulet beats Stagezero Life Sciences on 10 of the 10 factors compared between the two stocks.

About Stagezero Life Sciences

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.